Biocytogen Pharmaceuticals (Beijing) Co., Ltd. presented a monthly return of equity movements for the period ended January 31, 2026. The total authorized share capital remained at RMB 446,898,420, comprising RMB 110,781,920 in H shares and RMB 336,116,500 in A shares.

According to the announcement, there were no changes to the number of issued shares for either the H-share or A-share classes during the reporting period. The H-share count stood at 110,781,920, while the A-share count remained 336,116,500. No treasury shares or other share movements were reported.

In addition, the public float requirement for the listed H shares was met as of the end of January 2026, with no disclosures regarding any non-compliance. The company did not report any details on share options, warrants, convertibles, or other share issuance arrangements.